Eylea Market Report 2026

The eylea market size has grown strongly in recent years. It will grow from $10.51 billion in 2025 to $11.15 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of age-related macular degeneration, aging global population, strong clinical efficacy of anti-vegf drugs, increased ophthalmology specialty centers, reimbursement support for retinal therapies.

The eylea market size is expected to see strong growth in the next few years. It will grow to $14.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing diabetic population, expansion into additional retinal disorders, long-acting formulation development, improved drug delivery formats, increasing access in emerging markets. Major trends in the forecast period include extended-interval anti-vegf therapies, shift toward prefilled syringe adoption, growing use in diabetic retinopathy treatment, increased hospital-based intravitreal procedures, focus on real-world evidence and outcomes.

The rising prevalence of ocular diseases is expected to drive the growth of the Eylea market. Ocular diseases are eye conditions that impair normal eye function and negatively affect vision and visual clarity. These conditions often remain asymptomatic until they reach advanced stages. Eylea is used to treat ocular disorders such as wet age-related macular degeneration (AMD) and glaucoma, which damage the retina or macula and impair vision. Eylea works by inhibiting the protein responsible for the formation of fragile new blood vessels and by reducing retinal swelling caused by blocked blood vessels. For example, in 2024, the BrightFocus Foundation, a U.S.-based nonprofit organization dedicated to research on macular degeneration and glaucoma, reported that approximately 80 million people worldwide were living with glaucoma, a figure projected to increase to 111 million by 2040. Therefore, the growing incidence of ocular diseases is fueling the expansion of the Eylea market.

Leading companies in the Eylea market are focusing on the development of biologic therapies, such as aflibercept biosimilars, to gain a competitive edge. An aflibercept biosimilar is a biologically equivalent version of the reference drug aflibercept, intended to have no clinically meaningful differences while providing a more cost-effective treatment option for certain eye conditions. For example, in September 2023, Biocon Biologics Ltd., an India-based biopharmaceutical company, received marketing authorization from the European Commission (EC) for YESAFILI, an aflibercept biosimilar, in the European Union (EU). This authorization followed a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI is an ophthalmic product developed to treat multiple eye conditions, and its approval confirms its comparability in quality, safety, and efficacy to the reference product Eylea (aflibercept).

In January 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, acquired the exclusive commercialization rights to an Eylea biosimilar candidate from Klinge Biopharma GmbH for $32.5 million. This agreement underscores the company’s commitment to expanding treatment options and improving access for physicians and patients seeking high-quality, cost-effective alternatives to anti-VEGF therapies across healthcare settings. Klinge Biopharma GmbH is a Germany-based pharmaceutical company that develops ocular disease therapies, including Eylea biosimilars.

Major companies operating in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc.

North America was the largest region in the eylea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eylea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created moderate cost pressures in the eylea market by increasing prices of imported biologic raw materials, sterile packaging components, and ophthalmic delivery systems used in manufacturing. These impacts are most evident in prefilled syringe and vial packaging segments and across regions reliant on cross-border pharmaceutical supply chains, including parts of Asia-Pacific and Europe. Higher costs can affect hospital procurement budgets and retail pharmacy pricing. However, tariffs are also encouraging localized biologics manufacturing, supply chain diversification, and investments in regional fill-finish capabilities, which may strengthen long-term market resilience.

The eylea market research report is one of a series of new reports that provides eylea market statistics, including eylea industry global market size, regional shares, competitors with a eylea market share, detailed eylea market segments, market trends and opportunities, and any further data you may need to thrive in the eylea industry. This eylea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eylea is an injectable eye medication that helps reduce vision loss and treat specific ocular conditions by preventing leakage and abnormal blood vessel growth in the back of the eye. It is mainly prescribed for the treatment of age-related macular degeneration (AMD).

The primary forms of Eylea consist of prefilled syringe packages and vial packages. A prefilled syringe package is a single-use syringe that is supplied already filled with the drug. Eylea is used in the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other eye conditions, and is administered in settings such as hospitals, retail pharmacies, and other healthcare facilities.

The eylea market consists of sales of single-dose vials and single-dose prefilled syringes of Eylea. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.